PAMELA HILL: Open Payments
NPI 1720178502 · FLORENCE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$651 in 37 payments from 14 companies in 2025. Trend: 2023 $1,284 · 2024 $807 · 2025 $651
Food & beverage: $651
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $159 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $76 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $74 |
| Esperion Therapeutics, Inc. | 4 | $71 |
| ABBVIE INC. | 3 | $46 |
| Lilly USA, LLC | 2 | $39 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Novo Nordisk Inc | 2 | $32 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
Products named: AIRSUPRA, JARDIANCE, XIFAXAN, NEXLETOL, Kerendia, TRELEGY ELLIPTA, FARXIGA, Ozempic.
Industry payments across AL — which companies pay providers there.
